Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

A. D. Struthers67 enrolled

Overview

Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Kidney Disease Left Ventricular Hypertrophy

Interventions

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * CKD stage 3 * Echo LVH Exclusion Criteria: * Known heart failure * Patients already on Allopurinol * Patients with gout * Patients with hepatic disease * Contraindications to MRI, including severe claustrophobia * Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine * Malignancy or other life threatening disease * Pregnancy or lactating women * Patients unable to provide written consent

Outcomes

Primary Outcomes

Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients

Time frame: 9 months

Secondary Outcomes

Secondary objective is to see if Allopurinol reduces endothelial dysfunction in this group of CKD patients